- FDA approval of a new once-daily pancreatic cancer pill
- How the treatment targets the RAS protein linked to tumor growth
- Why the medicine was fast-tracked ahead of schedule
- Survival results from the clinical trial
- The patients who can receive the drug and its reported side effects
- Why this matters for a disease with limited treatment options
The FDA has given the green light to a new once-a-day pill for advanced pancreatic cancer, a disease that has long been one of the toughest battles in oncology. The drug, Rasonque, is aimed at adults with metastatic pancreatic cancer who have already tried treatment or who cannot take certain combination therapies, and it arrived far earlier than expected.
What makes the pill stand out is the way it works. Manufactured by Revolution Medicines, Rasonque is designed to block several forms of the RAS protein, a major engine behind tumor growth in pancreatic cancer. That matters because RAS has been a notoriously hard target, and getting a drug to move the needle here is a big deal.
The FDA said the medicine offers a new option for patients facing an aggressive cancer that has been difficult to treat for decades. Acting FDA Commissioner Kyle Diamantas said, “Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer. It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible,” in a press release.
He also added, “I am immensely proud of the dedicated FDA scientists whose fast, thorough review and relentless commitment made this groundbreaking milestone a reality.” The agency moved quickly on the application, approving it more than six months before its review deadline.
The speed was no accident. Regulators had already given the drug priority review, orphan drug status and breakthrough therapy designation, all signs that the agency saw real promise in the data. The application was also handled through the FDA commissioner’s National Priority Voucher pilot program, a pathway built to speed access to treatments viewed as especially important.
Before the final approval, the FDA issued a “safe to proceed” letter in May, which opened an expanded access protocol. That allowed some patients to receive the drug before the formal blessing came down, a move that can matter a lot when time is short and options are thin.
The clinical trial results are the part that really turned heads. In a randomized, open-label study of 500 patients with previously treated metastatic disease, people taking Rasonque had a median overall survival of 13.2 months, compared with 6.7 months in the standard chemotherapy group.
That kind of difference is hard to ignore in pancreatic cancer, where gains are often measured in tiny increments. The disease makes up a relatively small slice of total cancer diagnoses, but it is responsible for a far larger share of deaths because it is often found late and can spread fast.
Pancreatic adenocarcinoma accounts for up to 95% of the roughly 67,000 pancreatic cancer cases seen each year, according to the National Cancer Institute. Even though it represents only about 3.2% of all cancer diagnoses, its death toll is out of proportion to its size, which is exactly why new treatment options draw so much attention.
Angelo de Claro, M.D., director of the FDA’s Oncology Center of Excellence, said, “This drug showed unprecedented results in an area of high unmet need,” and that fits the broader reaction around the approval. For patients who have already been through standard treatment, every extra month can carry real weight.
The drug is not without risks, though, and the safety profile matters just as much as the headline survival numbers. The most common side effects seen in trials included rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, reduced appetite and hemorrhage.
That list is a reminder that even a promising cancer drug can come with a rough ride. Still, for people dealing with metastatic pancreatic cancer, a once-daily pill that directly targets the machinery driving the disease can feel like a rare opening in a field that has offered very few of them.
Anna Berkenblit, M.D., chief scientific and medical officer of the Pancreatic Cancer Action Network, said, “Today’s landmark approval is the most significant advance we have seen in the fight against pancreatic cancer, a devastating disease,” and she pointed to the possibility of more time, better quality of life and continued progress.
That sense of momentum is exactly what makes this approval land so hard. A drug that can be taken daily, reach patients sooner than expected and nearly double survival in a late-stage setting is the kind of development that shakes up a field long used to bad news and slim odds.
